Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07782970 SHR-1905 Nasal Polyps Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07782970 clinical trial report covering SHR-1905, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07782957 SHR-1905 Nasal Polyps Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07782957 clinical trial report covering SHR-1905, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07782112 Enzalutamide Salivary Gland Adenoma, Pleomorphic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07782112 clinical trial report covering Enzalutamide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07785843 Human papillomavirus 9-valent vaccine, recombinant (Merck Sharp & Dohme) Human Papillomavirus Infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07785843 clinical trial report covering Human papillomavirus 9-valent vaccine, recombinant (Merck Sharp & Dohme), Phase 3, endpoints, sponsor, geography
Latest Hotspot
8 min read
NCT07781293 Lurasidone Hydrochloride Recurrent major depressive disorder with atypical features Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07781293 clinical trial report covering Lurasidone Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07783321 PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical) Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07783321 clinical trial report covering PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical), Phase 3, endpoints, sponsor, geography, readout timing a
Latest Hotspot
8 min read
NCT07782827 Obudanersen Angelman Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07782827 clinical trial report covering Obudanersen, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07782671 Nicotinamide riboside Peripheral arterial occlusive disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07782671 clinical trial report covering Nicotinamide riboside, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07784101 Mesutoclax Mantle cell lymphoma refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07784101 clinical trial report covering Mesutoclax, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07786662 Dexamethasone Haemophilus influenzae pneumonia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07786662 clinical trial report covering Dexamethasone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07784036 Fulvestrant PIK3CA mutation/HR-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07784036 clinical trial report covering Fulvestrant, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07787260 Poterepatide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07787260 clinical trial report covering Poterepatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.